Last reviewed · How we verify

Niacin/ Laropiprant — Competitive Intelligence Brief

Niacin/ Laropiprant (Niacin/ Laropiprant) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipid-modifying agent; prostaglandin D2 receptor antagonist. Area: Cardiovascular.

marketed Lipid-modifying agent; prostaglandin D2 receptor antagonist DGAT2 (niacin); DP1 prostaglandin receptor (laropiprant) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Niacin/ Laropiprant (Niacin/ Laropiprant) — Ludwig-Maximilians - University of Munich. Niacin reduces triglycerides and LDL cholesterol while raising HDL cholesterol; laropiprant is a prostaglandin D2 receptor antagonist that reduces niacin-induced flushing.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Niacin/ Laropiprant TARGET Niacin/ Laropiprant Ludwig-Maximilians - University of Munich marketed Lipid-modifying agent; prostaglandin D2 receptor antagonist DGAT2 (niacin); DP1 prostaglandin receptor (laropiprant)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipid-modifying agent; prostaglandin D2 receptor antagonist class)

  1. Ludwig-Maximilians - University of Munich · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Niacin/ Laropiprant — Competitive Intelligence Brief. https://druglandscape.com/ci/niacin-laropiprant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: